We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Cidara Therapeutics Inc (CDTX) USD0.0001

Sell:$23.03 Buy:$23.44 Change: $0.17 (0.70%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$23.03
Buy:$23.44
Change: $0.17 (0.70%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$23.03
Buy:$23.44
Change: $0.17 (0.70%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Contact details

Address:
6310 Nancy Ridge Dr Ste 101
SAN DIEGO
92121-3209
United States
Telephone:
+1 (858) 7526170
Website:
https://www.cidara.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CDTX
ISIN:
US1717572069
Market cap:
$256.30 million
Shares in issue:
10.94 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jeffrey Stein
    President, Chief Executive Officer, Director
  • Preetam Shah
    Chief Financial Officer
  • Shane Ward
    Chief Operating Officer, Company Secretary
  • Leslie Tari
    Chief Scientific Officer
  • Jim Beitel
    Chief Business Officer
  • Taylor Sandison
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.